论文部分内容阅读
目的观察康莱特注射液联合DC-CIK细胞免疫治疗常见恶性肿瘤患者的细胞免疫功能及疗效,探讨康莱特注射液在恶性肿瘤生物细胞免疫治疗中的作用。方法选取符合西医诊断标准及中医气阴两虚或脾虚湿困型证候诊断标准的恶性肿瘤患者75例,随机分为对照组(30例)和治疗组(35例)。对照组予DC-CIK细胞治疗,治疗组予DC-CIK细胞联合康莱特注射液治疗。观察两组患者治疗前后T细胞亚群、临床疗效等。用SPSS 13.0对数据进行t检验和χ~2检验。结果联合治疗组患者经过治疗后,CD3~+、CD4~+CD56~+、CD8~+T淋巴细胞比率均较治疗前、对照组治疗后显著升高,差异均有统计学意义(P<0.05)。对照组治疗有效率为40%,肿瘤控制率为48.57%;联合治疗组治疗率有效为57.50%,肿瘤控制率为80.00%。两组治疗有效率比较差异无统计学意义(χ~2=1.4655,P>0.05),肿瘤控制率比较差异有统计学意义(χ~2=4.2834,P<0.05)。结论采用康莱特注射液联合DC-CIK治疗方法能够提高免疫细胞功能、提高疗效,具有较强的临床推广价值。
Objective To observe the effect of Kanglaite injection combined with DC-CIK cell immunotherapy on the cellular immune function in patients with common malignant tumors and to explore the role of Kanglaite injection in the treatment of malignant tumor cells. Methods Totally 75 patients with malignant tumor who meet the diagnostic criteria of Western medicine and the diagnostic criteria of Qi-Yin Deficiency or Spleen-Qi Deficiency syndrome were randomly divided into control group (30 cases) and treatment group (35 cases). The control group was treated with DC-CIK cells. The treatment group was treated with DC-CIK cells combined with KLT. Before and after treatment, the T cell subsets and clinical efficacy were observed. Data were tested for t-test and chi-square test using SPSS 13.0. Results After treatment, the ratio of CD3 ~ +, CD4 ~ + CD56 ~ + and CD8 ~ + T lymphocytes in the combined treatment group was significantly higher than that before treatment and after treatment in the control group (P <0.05 ). The effective rate of the control group was 40% and the tumor control rate was 48.57%. The effective rate of the combined treatment group was 57.50% and the tumor control rate was 80.00%. There was no significant difference between the two groups in the treatment efficiency (χ ~ 2 = 1.4655, P> 0.05). The difference in tumor control rate was statistically significant (χ ~ 2 = 4.2834, P <0.05). Conclusion Kanglaite injection combined with DC-CIK treatment can improve immune cell function and improve efficacy, with strong clinical value.